论文部分内容阅读
目的观察米索前列醇联合缩宫素预防孕产妇产后出血的临床效果及安全性。方法 423例孕产妇分为两组,对照组肌注缩宫素,观察组直肠给药米索前列醇,肌注缩宫素,比较两组产后2 h、24 h出血情况、血压和出血发生率以及不良反应发生率。结果观察组的产后2 h、24 h出血量明显低于对照组(P<0.05),两组血压治疗前后以及治疗后两组组间比较,均差异无统计学意义(P均>0.05)。产后2 h,24 h出现发生率比较差异有统计学意义(P<0.05),不良反应发生率低。结论米索前列醇联合缩宫素预防孕产妇产后出血,临床效果明显,值得推广。
Objective To observe the clinical effect and safety of misoprostol combined with oxytocin in preventing maternal postpartum hemorrhage. Methods 423 pregnant women were divided into two groups. The control group received intramuscular injection of oxytocin. The patients in the observation group received rectal administration of misoprostol and intramuscular oxytocin. The bleeding of 2 h and 24 h postpartum was compared between the two groups. Blood pressure and bleeding occurred Rate and incidence of adverse reactions. Results The amount of bleeding at 2 h and 24 h after delivery in observation group was significantly lower than that in control group (P <0.05). There was no significant difference in blood pressure before and after treatment and after treatment between two groups (P> 0.05). The incidence of postpartum 2 h, 24 h was significantly different (P <0.05), the incidence of adverse reactions was low. Conclusion Misoprostol combined with oxytocin to prevent postpartum hemorrhage in pregnant women, the clinical effect is obvious, it is worth promoting.